5
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour stage
- Metastatic and advanced
- Control Arm
- Platinum-based chemotherapy
- Treatment Setting
- 1st line metastatic and advanced NSCLC with PD-L1>50%
- Trial Name
- KEYNOTE-24
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- PFS Control
- 6 months
- PFS Gain
- 4.3 months
- PFS HR
- 0.50 (0.37-0.68)
- OS Control
- 14.2 months
- OS Gain
- 15.8 months
- OS HR
- 0.63 (0.47-0.86)
- Toxicity Comment
- Improved toxicity profile
Final Score (after adjustments)
- Preliminary non-curative score
- 4
- Toxicity adjustment
- 1+
- Final non-curative Score
- 5
- Last update
- 15.09.2020
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate